Women with pulmonary arterial hypertension have greater response to treatment than men

September 28, 2011

Pulmonary arterial hypertension (PAH) patients of different sexes and races may respond differently to treatment with commonly used medications for the disease, says a new study from researchers at Perelman School of Medicine at the University of Pennsylvania.The results of the study are published online ahead of print in the journal CHEST.

"Over the past decade, treatment outcomes have improved for PAH patients as a group, but little is known about which patients are most likely to respond to specific treatments," said senior study author Scott Halpern, MD, PhD, MBE, assistant professor of and Epidemiology. "Our research has shown for the first time that differences in the behavior of the disease between men and women and between whites and blacks may lead to differences in patients’ responses to treatment with commonly used PAH oral medications."

PAH is a disease in which the blood pressure in a patient's lungs becomes dangerously high. That high blood pressure puts a strain on the heart, leading to shortness of breath, leg swelling, and chest pain. PAH worsens over time and can be fatal.

The current study evaluated pooled data from six randomized placebo-controlled trials of endothelin receptor antagnosists, or ERAs. ERAs were the first oral therapies approved by the FDA for use in PAH and remain among the most commonly used drugs to treat the condition. A total of 1,130 patients were included in the analyses. The researchers specifically estimated the differences in the effect of treatment (ERAs vs. placebo) between men and women and between white or black patients in terms of the change in six-minute walk distance from baseline to 12 weeks.

The response to ERAs, relative to that of placebo, was more than twice as great among women as among men, and was much greater among whites than among blacks. "The available evidence certainly suggests that whites with PAH have stronger responses to these drugs than do blacks, but future research is needed to better understand how these drugs work among blacks, who have not been highly represented in studies to date," said study co-author Steven Kawut, MD, MS, associate professor of Medicine and Epidemiology and director of the Pulmonary Vascular Disease Program at Penn.

"In our study, women with PAH obtained the greatest response to the ERAs, and we also found that whites may experience a greater treatment benefit than blacks," said Nicole Gabler, PhD, MHA, the study’s lead author and a post-doctoral researcher in Penn’s Center for Clinical Epidemiology and Biostatistics. "This does not necessarily mean that or physicians should change their current treatment for PAH. However, the findings support the important possibility that biologic differences between and races, or distinct characteristics in the disease that affects these subgroups, could lead to more effective therapies in the future."

The authors suggest that based on their observations, future studies are needed to explore the biologic underpinnings of PAH that account for why women and whites may show a greater response to ERA and ways to optimally match the therapy to the patient.

Explore further: Heart drugs ineffective in treating pulmonary arterial hypertension

More information: chestjournal.chestpubs.org/con … est.11-0404.abstract

Related Stories

Heart drugs ineffective in treating pulmonary arterial hypertension

May 18, 2011
Despite their beneficial effects in treating heart disease, neither aspirin nor simvastatin appear to offer benefit to patients suffering from pulmonary artery hypertension (PAH), according to a National Institutes of Health ...

New study may lead to quicker diagnosis, improved treatment for fatal lung disease

July 11, 2011
One-fifth of all patients with pulmonary arterial hypertension suffer with the fatal disease for more than two years before being correctly diagnosed and properly treated, according to a new national study led by researchers ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.